Neoplasms constituted an enormous burden and contributed to an estimated 8.2 million deaths in 2012 worldwide. FOXO1 (forkhead box O1), a member of the forkhead box (FOX) family, is a transcriptional factor involved in diverse cellular functions. Herein, we concentrate on recent studies of the antineoplastic roles of FOXO1 in neoplasms. This article may serve as a guide for future research and identify FOXO1 as a potent therapeutic target in neoplasms.
Cardiovascular diseases, cerebrovascular diseases and neoplasms are three major killers among human across the world. [1] [2] [3] [4] [5] [6] Neoplasms cause an enormous burden on society in both developed and developing countries. The occurrence of neoplasms is increasing because of the growth and aging of the population, as well as increasing exposure to established risk factors. According to the Cancer Statistics from the American Cancer Society, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States in 2017 7 and the majority of patients cannot be diagnosed until a middle/advanced stage and thus fail to receive an improved outcome. [8] [9] [10] [11] [12] Therefore, future research is urged to search for a novel molecular target to redeem the deficiency of current therapies. Among all molecules, FOXO1 (Forkhead box O1) is of great interest and potential. The FOX family was identified in Drosophila 20 years ago. Scientists discovered that mutation of forkhead, the region-specific homeotic gene, may contribute to abnormal embryos. [13] [14] [15] [16] FOXO belongs to the FOX family and is referred to as forkhead rhabdomyosarcoma transcription factor (FKHR). 14, [17] [18] [19] It was first reported by Weigel's group in 1989 20 and identified as a pivotal transcriptional factor in 1990. 21 So far, there is one genotype in invertebrates and four genotypes in vertebrates, including FOXO1, 3, 4 and 6. Research has suggested that FOXO1 has antineoplastic actions in digestive system cancers, [22] [23] [24] prostate cancer, 25 breast cancer, 26 hematological neoplasms 27, 28 and others, 29, 30 although its antineoplastic actions have not been well discussed. Therefore, we carefully reviewed previous literature and completed this article ( Fig. 1 and Table 1 ). This article is dedicated to the antineoplastic roles of FOXO1 in neoplasms. First, we introduce the background of neoplasms and FOXO1. Second, we summarize the close relationship between FOXO1 and carcinogenesis. Third, we analyze the antineoplastic mechanisms of FOXO1, including antiproliferation, antiprogression and proapoptosis mechanisms. Ultimately, we discuss the potential directions and differing opinions concerning FOXO1. This article highlights the recent advances and provides a detailed picture of FOXO1, which might be helpful in drug design and clinical therapy for neoplasms.
FOXO1 and Carcinogenesis
Carcinogenesis-or tumorigenesis-is a pathological alteration of epithelial/mesenchymal cells under the stimulation of risk factors, namely, the epithelial-mesenchymal transformation (EMT). [31] [32] [33] This process is characterized by alterations at the cellular, genetic, and epigenetic levels and abnormal cell division. Normally the balance between proliferation and programmed cell death (apoptosis) is maintained to ensure the integrity of tissues and organs. Previous studies have demonstrated that low levels or activity of FOXO1 have a close relationship with tumorigenesis. 34, 35 FOXO1 silencing is related to suppressed EMT in A549 lung adenocarcinoma epithelial cells, which is evidenced by decreased epithelial markers (E-cadherin) and enhanced mesenchymal markers (SNAIL, SLUG). 36 Helicobacter pylori infection is the major risk factor for gastric cancer. In human gastric cancer epithelial cells, phosphorylated FOXO1 (pFOXO1), the inactive form of FOXO1, is highly expressed in the cytoplasm rather than the nucleus, revealing that the disruption of FOXO1 subcellular location might induce early gastric carcinogenesis among Helicobacter pylori-infected patients. 37 In 298 human gastric carcinoma specimens, the levels of pFOXO1 were high and positively correlated with the expression of nuclear RelA and cyclin D1. Cell culture experiments demonstrated that FOXO1 overexpression by transfection of the FOXO1-AAA mutant gene suppresses NF-jB signaling and gastric carcinogenesis. 38 At the molecular level, Procaccia's group discovered that direct binding of MEK1 and MEK2 to Akt induces FOXO1 phosphorylation and thus contributes to cell migration and metastasis in a mouse breast cancer model. 35 These findings all demonstrate that low levels/activity of FOXO1 is a possible factor for early carcinogenesis, and activated FOXO1 can inhibit carcinogenesis ( Figs. 1 and 2 ).
Anticancer Mechanisms of FOXO1

Apoptosis
Apoptosis is also referred to as programmed cell death. [39] [40] [41] [42] [43] [44] [45] [46] Resisting apoptosis is one of the most prominent characteristics of neoplasms. MHY-449, a novel cytotoxic drug, can induce apoptotic cell death in human PC3 prostate cancer cells by downregulating the phosphorylation levels of FOXO1, which is evident in the increased activity of caspase-3, caspase-8 and caspase. 47 Qiong and colleagues discovered that the dephosphorylation of FOXO1 by wortmannin promotes the apoptosis of non-Hodgkin's lymphoma (Namalwa and Jurkat cell lines). Meanwhile, wortmannin also activates FOXO1 via Bim signaling, further resulting in cancer apoptosis. 48 Restoration of FOXO1 contributes to reduced cancer cells due to a decrease in cell proliferation and induction of apoptosis in MCF-7 breast cancer cells. 49 Lin et al. found that FOXOs-deficient cells exhibit decreased apoptosis under energy stress while FOXOs potentiate energy stress-induced apoptosis. Notably, they discovered that low expression of FOXOs correlates with poor clinical outcomes in renal cancer patients. 50 Additionally, curcumin induces apoptosis in pancreatic cancer cells through the activation of FOXO1, which is characterized by a reduced Bcl-2/Bax ratio and increased caspase 9/3 ratio. 51 The evidence all suggests that activated and dephosphorylated FOXO1 can induce apoptosis in cancer cells.
Proliferation
Unlimited proliferation is also a classic feature of neoplasms and may cause immense damage to normal cells. [52] [53] [54] [55] barrestin 2, a corepressor of the androgen receptor, promotes the proliferation of cancer cells in castration-resistant prostate cancer by phosphorylating FOXO1. b-arrestin 2 also inhibits FOXO1 activity in an Akt-independent manner and delays FOXO1 dephosphorylation, thereby contributing to the proliferation of tumor cells. 56 Acylglycerol kinase promotes the proliferation of breast cancer cells by downregulating FOXO1 activity and activating the Akt signaling pathway, characterized by enhanced G1-S phase transition and upregulation of the cell cycle regulator cyclin D1. However, activation of FOXO1 reverses this effect and inhibits tumor proliferation. 57 Together, these studies suggest that FOXO1 is a potential antiproliferation molecule in neoplasms.
Progression
Tumor progression is the last phase during tumor development and is characterized by increased growth speed and invasiveness, as well as phenotypic alterations.
57-61 b-arrestin 2 enhances cell viability by downregulating FOXO1, whereas siRNAmediated b-arrestin 2 silencing lowers cell viability and tumor metastasis, which is correlated with increased FOXO1 activity. 56 FOXO1 inhibits Runx2-induced migration and invasion of PC-3 prostate cancer cells, detected by Matrigel invasion assay. However, silencing of endogenous FOXO1 enhances tumor migration in a Runx2-dependent manner. Notably, the level of FOXO1 in the nucleus is inversely correlated with the expression of Runx2 in a cohort of prostate cancer specimens from patients with lymph node and bone metastasis. These data revealed that FOXO1 can serve as a negative regulator of Runx2 to resist the progression of prostate cancer cells. 25 microRNAs (miRs), which are noncoding 20-22 nucleotide single-stranded RNAs, result in translational repression and gene silencing of target genes. 62, 63 The FOXO1 3 0 UTR, functioning as a competitive endogenous RNA, is a direct target of miR-9 and may function as a miR inhibitor. miR-9 binds to the FOXO1 3 0 UTR and inhibits the metastasis of breast cancer cells. The results demonstrated that miR-9 binds to the 3 0 UTR of both FOXO1 and E-cadherin, and there is competition between the 3 0 UTR of FOXO1 and E-cadherin. Specifically, the bound 3 0 UTR of FOXO1 inhibits the metastasis of breast cancer cells via out competing E-cadherin. 64 Additionally, FOXO1 silencing enhances angiogenesis of gastric cancer by upregulating the heat shock factor HIF-1a and vascular endothelial growth factor (VEGF), while FOXO1 activation reverses this process and restrains tumor progression. 65 Taken together, this research reveals that FOXO1 exerts antineoplastic mechanisms via antiprogression, antiproliferation and proapoptosis mechanisms (Fig. 3) .
Roles of FOXO1 in Diverse Human Neoplasms
Digestive system cancers Digestive system neoplasms-including hepatocellular carcinoma (HCC), gastric cancer, colorectal cancer, pancreatic cancer and esophageal cancer-caused an estimated 3 million deaths in 2012 worldwide. 44, 66 Rapamycin can induce the inactivation of FOXO1 and promote the proliferation of colorectal cancer cells, thereby lowering the anticancer efficacy during chemotherapy. As FOXO1 is a tumor-inhibiting molecule, this finding explains why treatment with rapamycin may contribute to drug resistance and tumor growth, possibly via downregulating FOXO1. 67 High levels of serum insulinlike growth factor (IGF)-1 and the IGF-1 receptor (IGF-1R) exist universally in gastric cancer cells. The IGF-1/Akt pathway promotes the phosphorylation of FOXO1, which is correlated with increased proliferation and reduced apoptosis of cancer cells 68 (Fig. 2) . Sulforaphane (SFN), a compound from the isothiocyanate group, inhibits cell proliferation and induces apoptosis through caspase-3 signaling in pancreatic cancer. Specifically, SFN suppresses phosphorylation of Akt and extracellular signal-regulated kinase (ERK), which activates FOXO1 and contributes to tumor suppression. 69 HMG boxcontaining protein 1 (HBP1) is a regulator of the cell cycle and differentiation. Analysis of 30 noninvasive and invasive oral tumor specimens indicated that mean mRNA levels of both FOXO1 and HBP1 are significantly lower than those of control tissues, and a low FOXO1 and HBP1 status (<0.3-fold of the control) is associated with enhanced invasiveness of oral tumors. Specifically, HBP1 knockdown potently downregulates FOXO1 and promotes the expression of malignant phenotypes, colony formation and invasion of oral cancer. 70 miRs play a pivotal role in tumor progression via FOXO1 signaling. miR-142-5p overexpression significantly induces cell apoptosis and elevates the protein expression levels of FOXO1 in HCC cells. However, cells transfected with a miR-142-5p inhibitor show contrasting results and low levels of FOXO1. 71 Islam et al. discovered that the expression of miR-498 and FOXO1 is low in esophageal squamous cell carcinoma (ESCC) tissues. However, miR-498 overexpression activates the FOXO1/KLF6 transcriptional axis and promotes apoptotic cell death of ESCC. 72 In conclusion, FOXO1 acts as a tumor repressing factor in digestive system neoplasms, highlighting FOXO1 as a drug candidate in cancer therapy.
Prostate cancer
Prostate cancer is one of the most common neoplasms among aging males. 73 As of 2011, prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer-related deaths in males worldwide. 74 Zhang's group discovered that methylseleninic acid (MSA) treatment leads to rapid expression of FOXO1 as well as an increase in FOXO1 transcriptional activity, while blocking FOXO1 by gene silencing abolishes the pro-apoptosis actions of prostate cancer, suggesting that FOXO1 plays a critical role in mediating the apoptotic effect of MSA. 75 miR-370 is able to downregulate FOXO1 by directly targeting the 3 0 -untranslated region of FOXO1 and induces proliferation of human prostate cancer cells. This reveals that miR-370 plays an important role in the proliferation of human prostate cancer cells by directly blocking the tumor suppressor FOXO1. 62 Additionally, leptin also promotes the phosphorylation of FOXO1 via PI3K signaling and promotes the development of prostate cancer, which is concomitant with enhanced tumor proliferation, migration and invasion. However, the PI3K inhibitor LY294002 inhibits the anticancer actions of FOXO1. This suggests that exposure to leptin induces tumor proliferation, migration and invasion of prostate cancer cells through the inactivation of FOXO1. 76 
Breast cancer
Breast cancer is one of the most frequent tumors among women and still represents a major cause of mortality. [77] [78] [79] Cancer cells are characterized by metabolic alterations, including depressed mitochondrial oxidation, enhanced glycolysis and pentose phosphate shunt flux to support rapid cell growth, which is called the Warburg effect. 19, 80 As for the enhanced glycolysis under Warburg effect, cancer cells use other biosynthetic pathways of glucose, such as pentose phosphate, hexosamine and amino acid anabolism pathways, which are essential to meet the increased biosynthetic needs and to support cancer cell survival. 19 Fodor et al. discovered that combined treatment with AICAR and methotrexate arrests the cell cycle and reverses the Warburg effect in MCF-7 breast cancer cells by activating FOXO1 signaling. 77 Tumor-initiating cells (TIC) account for chemoresistance, tumor recurrence and metastasis and therefore represent a major problem in tumor therapy. Cyclin-dependent kinase (Cdk5) inhibition induces apoptosis of tumors by stabilizing the transcription factor FOXO1, which is correlated with increased levels of the proapoptosis protein, Bim. 81 Exogenous IGF-1R promotes the expression of FOXO1 and insulin-like growth factor binding protein-1 (IGFBP-1), evidenced by suppression of breast cancer, whereas IGF-1R knockdown decreases FOXO1 protein levels and promotes the proliferation of MCF-7 cells. 82 Moreover, some other studies have demonstrated that FOXO1 can exert antitumor actions in breast cancer, while a detailed description is beyond the scope of this article.
83-85
Hematological neoplasms
Hematologic neoplasms, including leukemia and lymphoma, are the leading causes of death among children and adolescents. 66, 86 Pre-B cell receptor (BCR) signaling and tyrosine kinase were recently introduced as therapeutic targets for patients with B-cell acute lymphoblastic leukemia (B-ALL). Kohrer et al. discovered that Pre-BCR signaling activates the FOXO1 pathway and inhibits the development of B-ALL, indicating FOXO1 as an antitumor molecule in leukemia.
87
FOXO1 inhibits the proliferation of cancer cells in chronic lymphocytic leukemia (CLL) 88 and chronic myelogenous leukemia (CML), 89 thereby exerting antitumor actions in hematologic neoplasms. Curcumin, a well-known bioactive compound derived from turmeric, 90 potentiates antitumor activity of Lasparaginase via activation of FOXO1 and inhibition of Akt signaling in ALL, which is concomitant with enhanced apoptosis and suppressed proliferation of leukemia cells. 91 Apart from leukemia, FOXO1 also performs antitumor actions in lymphomas. [92] [93] [94] Diffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of newly diagnosed lymphomas and has an overall cure rate of 60%. 95, 96 Trinh et al. reported that FOXO1 mutation is associated with tumor development and decreased overall survival in patients treated with R-CHOP, indicating that FOXO1 mutation is a novel prognostic factor in DLBCL. 97 FOXO1 is downregulated in classical Hodgkin lymphoma (cHL) cell lines, whereas activation of FOXO1 induces apoptosis and blocks proliferation of cHL cells accompanied by cell cycle arrest in the G0/G1-phase. 27 Moreover, miR-21 directly targets and suppresses FOXO1 expression and subsequently inhibits Bim transcription in DLBCL cells, thereby delaying the development of DLBCL. 98 Together, these findings demonstrate that FOXO1 is a potent antineoplastic factor in hematologic neoplasms.
Other neoplasms
Additionally, FOXO1 also suppresses the growth and proliferation of other neoplasms. Bladder cancer is the most common malignancy of the urinary system and the number one cause of death in patients with urinary tract disease. 99 Limited expression of miR-145 promotes growth of T24T cells accompanied by the downregulation of FOXO1. In nonmetastatic T24 cells, miR-145 overexpression inhibits cell growth by upregulating FOXO1, whereas the knockdown of FOXO1 abolishes the miR-145-mediated inhibition of cell growth. 100 Lloreta's group analyzed 162 tissues from bladder cancer patients and discovered that FOXO1 downregulation and p53 overexpression are associated with worse outcomes and recurrences in bladder cancer, specifically in high grade (p 5 0.04) and in pT1 stage tumors (p 5 0.007). Interestingly, they discovered that testing for FOXO1 expression may provide relevant prognostic information on progression and recurrence of bladder cancer when p53 is highly expressed.
101
Lung cancer is the leading cause of death among all neoplasms. 102 [28808300]Propofol, a short-acting general anesthetic, reduces cell viability but induces apoptosis by activating FOXO1 under conditions of anesthesia safety. However, the miR-486 inhibitor reverses the antineoplastic effects of propofol and downregulation of FOXO1, suggesting that propofol might be an ideal anesthetic for lung cancer surgery via FOXO1 signaling. 30 Gan et al. discovered that FOXO1 is downregulated in renal cancer cells. FOXO1 can enhance a progression checkpoint to constrain mTORC1-activated renal tumorigenesis through upregulating miR-145, thereby inhibiting tumor development. 103 (Table 1) .
Prospects and Conclusion
Analogues or derivatives of FOXO1 can exert similar antineoplastic actions. FO1-6nls is a FOXO1-derived peptide that inhibits Cdk1/2-mediated phosphorylation of FOXO1 at the serine 249 residue in vitro and in vivo. Overexpression of FO1-6nls in prostate cancer cells not only blocks Cdk1/2-induced cytoplasmic localization of FOXO1 but also augments FOXO1's transcriptional activity, thereby contributing to the suppression of prostate cancer. 108 Compound 1a
(LOM612), a newly synthesized isothiocyanate that is a potent FOXO activator, induces nuclear translocation of FOXO1 and increases the activity of FOXO1 in a dosedependent manner in U2OS osteosarcoma cells and shows a potent antiproliferation and tumor-suppressing effect. 109 Moreover, there is study already stresses this point regarding the role of FOXO1 in clinic. Kim et al. studied human gastric carcinoma specimens and revealed that cytoplasmic pFOXO1 expression is positively correlated with the expression of several angiogenesis-related proteins (HIF-1a, NF-jB), compared with normal gastric tissues, suggesting that reduced expression of cytoplasmic pFOXO1 but enhanced expression of nuclear FOXO1 is a potential pathway for cancer treatment.
110
FOXO1 exerts antitumor actions via other mechanisms, including oxidative stress, autophagy and ubiquitination. Skp2, an oncogenic subunit of the Skp1/Cul1/F-box ubiquitin protein system (UPS), interacts with ubiquitinases and promotes the degradation of FOXO1. Expression of Skp2 promotes degradation of FOXO1 and abolishes the inhibitory effect of FOXO1 on cell proliferation and survival. Furthermore, expression of the FOXO1 protein is lost in a mouse lymphoma model where Skp2 is overexpressed. These data suggest that the Skp2-promoted ubiquitin-mediated proteolysis of FOXO1 plays a key role in tumorigenesis. 111 Constitutively photomorphogenic 1 (COP1) possesses E3 ubiquitin ligase activity and targets key transcription factors for proteasome-dependent degradation. 112 Expression of COP1 promotes the proliferation of CLL cells. Specifically, COP1 promotes cell cycle transition from G0/G1 to S phase by inhibiting FOXO1 and p21. 113 Sewastianik et al. discovered that thioredoxin (TXN) overexpression curtails p300-mediated FOXO1 acetylation and its nuclear translocation in response to oxidative stress, thus attenuating FOXO1 transcriptional activity concerning apoptosis and cell cycle inhibition. They also reported that FOXO1 knockdown with silenced TXN expression markedly reduces ROS-induced apoptosis in DLBCL, indicating that FOXO1 is the major sensor and effector of oxidative stress to perform its tumorsuppressing functions.
114 FOXO1 can be acetylated by dissociation from sirtuin-2, a NAD 1 -dependent histone deacetylase. Meanwhile, the acetylated FOXO1 binds to Atg7, an E1-following protein, and promotes the autophagy process and cell death in human colon tumors and a xenograft mouse model. 115 However, there are perspectives that question the positive roles of FOXO1 in neoplasms. FOXO1 synergizes with activated b-catenin in osteoblasts to initiate a program of gene expression that disrupts hematopoiesis by altering HSC lineage determination, ultimately leading to AML. In turn, stabilized b-catenin promotes expression of Notch ligands in osteoblasts through FOXO1, leading to activation of Notch signaling in HSCs. This suggests that FOXO1, a known tumor suppressor, assumes the opposite role in osteoblasts as a tumor inducer capable of triggering AML in response to activated b-catenin signaling. 28 Moreover, Zhao's group reported that cytosolic FOXO1 is essential for the suppression of colon cancer rather than nuclear FOXO1. They believed that cytosolic FOXO1 may induce autophagy and promotes cancer cell death, thereby exerting antineoplastic actions. 115 Lin et al. used anticarcinogen NVP-BEZ235 to treat renal cell carcinoma. They discovered that FOXOs deficiency promote cell proliferation suppression and cell death under NVP-BEZ235 treatment, thus potentiating NVP-BEZ235-induced renal tumor suppression in vivo. This suggests that FOXOs can promote tumor growth. 116 Hence further studies are required to determine the intrinsic mechanisms of FOXOs. Notably, FOXO1 is believed to act as an antineoplastic role by regulating cancer immunity. 117, 118 FOXO1 inactivation is essential for the migration of Treg cells that can suppress CD81 T-cell responses. Luo et al. discovered that FOXO1 unexpectedly inhibits active Treg-cell-mediated immune tolerance and enhances the antineoplastic actions in mice, which promotes FOXO1 as a novel molecule for breaking tumor immune tolerance. 119, 120 In addition, FOXO1 is critical for the maintenance of naive T cells through the signaling of adhesion protein L-selectin, chemokine receptor CCR7, transcription factor KLF2 and IL-7Ra, thus restraining the tumor growth. 118, 121 Current studies have revealed a sophisticated signaling network involving FOXO1 that confers promising directions for exploring the inherent mechanisms of cancer. However, FOXO1 research remains elusive, and new frontiers may include the following: (i) exploring upstream and downstream signaling to provide a comprehensive picture of the FOXO1 network; (ii) elucidating the biological actions of the FOXO family to facilitate understanding of FOXO1; (iii) speeding up the clinical trials of FOXO1-targeted drugs to verify their efficacy in neoplasms. Together, this article is devoted to the antineoplastic roles of FOXO1 and may facilitate future research and progress in neoplasms.
